Lung carcinogenesis in humans involves an accumulation of genetic and epigenetic changes that lead to alterations in normal lung epithelium, in situ carcinoma, and finally invasive and metastatic cancers. The loss of TGF-fi-induced tumor suppressor function in tumors is believed to play a pivotal role in this transition. Resistance to TGF-fi in lung cancers occurs mostly through loss of TGF-fi type II receptor (TliRII) expression, and our preliminary data suggest that expression of TliRII is lost or weak in 77% of human lung cancers. However, it is not known how TURN expression is lost during lung tumorigenesis. Our initial experiments have resulted in an important observation that activation of the MAPK/ERK pathway causes down-regulation of TfiRII through histone deacetylation and that DMA hypermethylation has no effect on TfiRII promoter activity. In addition, we have observed that TGF-li-induced tumor suppressor function is restored in TGF-li resistant lung cancer cells via exogenous TfiRII expression or with the treatment of histone deacetylase (HDAC) inhibitor (HDI). Since the majority of lung tumors are resistant to TGF-li due to loss of TliRII, we believe that the TGF-fi pathway could be a potential target of HDIs for chemothrapeutic intervention. We have formulated the following hypotheses: 1) Loss of TfiRII expression in lung cancer is mostly due to the epigenetic change, histone deacetylation, and promotes unresponsiveness to TGF-fi-induced tumor suppressor effects. 2) In the pre-malignant phase, the autocrine anti-proliferative effects of TGF-fi predominate. However, the balance shifts during tumor progression, and growth-promoting effects of TGF-fi become pronounced in the advanced stage. 3) Restoration of TGF-fi signaling by the HDI, MS-275, an anticancer drug currently in clinical trials, may be a potential alternative for therapeutic intervention of lung cancers. These hypotheses will be tested by the following specific aims: 1) To determine the molecular mechanism of down-regulation of TfiRII in lung cancer and how that can be targeted by HDAC inhibitors. 2) To determine the biological consequences of over-expression of TGF-fi and restoration of TGF-fi signaling in human lung cancer cell lines. The long term objective of this study is to determine, at the molecular level, the mechanism by which lung tumors become resistant to TGF-fi tumor suppressor function and to provide new insights into the mechanism by which HDIs target the TGF-fi pathway in lung cancer. Increased understanding of these mechanisms should help to improve drug development and treatment of lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA113519-04
Application #
7574523
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Woodhouse, Elizabeth
Project Start
2006-03-01
Project End
2011-01-31
Budget Start
2009-02-01
Budget End
2010-01-31
Support Year
4
Fiscal Year
2009
Total Cost
$238,105
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Surgery
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Datta, Raktima; Halder, Sunil K; Zhang, Binhao (2013) Role of TGF-? signaling in curcumin-mediated inhibition of tumorigenicity of human lung cancer cells. J Cancer Res Clin Oncol 139:563-72
Nagathihalli, Nagaraj S; Massion, Pierre P; Gonzalez, Adriana L et al. (2012) Smoking induces epithelial-to-mesenchymal transition in non-small cell lung cancer through HDAC-mediated downregulation of E-cadherin. Mol Cancer Ther 11:2362-72
Samanta, Debangshu; Kaufman, Jacob; Carbone, David P et al. (2012) Long-term smoking mediated down-regulation of Smad3 induces resistance to carboplatin in non-small cell lung cancer. Neoplasia 14:644-55
Samanta, Debangshu; Gonzalez, Adriana L; Nagathihalli, Nagaraj et al. (2012) Smoking attenuates transforming growth factor-?-mediated tumor suppression function through downregulation of Smad3 in lung cancer. Cancer Prev Res (Phila) 5:453-63
Samanta, Debangshu; Datta, Pran K (2012) Alterations in the Smad pathway in human cancers. Front Biosci (Landmark Ed) 17:1281-93
Reiner, Jennifer Elisabeth; Datta, Pran K (2011) TGF-beta-dependent and -independent roles of STRAP in cancer. Front Biosci (Landmark Ed) 16:105-15
Halder, Sunil K; Cho, Yong-Jig; Datta, Arunima et al. (2011) Elucidating the mechanism of regulation of transforming growth factor ? Type II receptor expression in human lung cancer cell lines. Neoplasia 13:912-22
Kashikar, Nilesh D; Zhang, Wanguang; Massion, Pierre P et al. (2011) Role of STRAP in regulating GSK3? function and Notch3 stabilization. Cell Cycle 10:1639-54
Reiner, Jennifer; Ye, Fei; Kashikar, Nilesh D et al. (2011) STRAP regulates c-Jun ubiquitin-mediated proteolysis and cellular proliferation. Biochem Biophys Res Commun 407:372-7
Rachakonda, G; Sekhar, K R; Jowhar, D et al. (2010) Increased cell migration and plasticity in Nrf2-deficient cancer cell lines. Oncogene 29:3703-14

Showing the most recent 10 out of 17 publications